ni Mary Gutierrez Almirañez | April 12, 2021
Gaganapin sa ‘Pinas ang clinical trial ng bakunang EuCorVac-19 na gawa ng South Korea upang labanan ang lumalaganap na COVID-19 pandemic, ayon sa Glovax Biotech Corporation ngayong araw, Abril 12.
Ayon kay CEO Giovanni Alingog, “The reason we wanted to do a clinical trial in the Philippines is most of the companies that were given EUA (emergency use authorization) in our country have not done a clinical trial locally. The reason we wanted to trial locally is to show, for ethnicity purposes, for Filipinos, that the vaccine is also effective and safe.”
Ngayong Abril ay nakatakdang isagawa ang combined phase 1 at phase 2 trial ng EuCorVac-19.
Batay pa sa pag-aaral, nagtataglay ito ng 91% hanggang 95% na efficacy rate.
Dagdag ni Alingog, “Because of the emergency purposes or the need of vaccine, we are asking the clinical research organizations and our FDA (Food and Drug Administration) to fast-track a bit our clinical trial so we can serve the Filipino people with a quality and safe vaccine from Korea.”
Samantala, iginiit naman ni Department of Health (DOH) Secretary Francisco Duque III na nakikipagtulungan na rin ang Glovax sa Department of Science and Technology (DOST) upang makapag-develop ang ‘Pinas ng sariling bakuna kontra COVID-19.
Sa ngayon, ang may emergency use authorization (EUA) pa lang na bakuna ay ang Pfizer-BioNTech, AstraZeneca, CoronaVac ng Sinovac, at ang Sputnik V ng Gamaleya Institute.
Komentarze